FUROXONE
LOE ApproachingNDAORALTABLET
Approved
Mar 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUROXONE is an oral small-molecule tablet approved in 1961 by Takeda for undisclosed indications. The specific mechanism of action and therapeutic uses are not publicly detailed in available data.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling a contracting commercial footprint and likely smaller team focus on generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FUROXONE currently has zero linked job openings and is not actively recruiting talent, reflecting its mature, LOE-approaching lifecycle. Roles on this product are likely administrative, cost-focused, and tied to market exit or generic transition strategy rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on FUROXONE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.